drug
MIFEPRISTONE
Marketedupdated 6mo agoby $CORT CORCEPT THERAPEUTICS INC
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3all catalysts(6)
approval · 6
Apr 11, 2019
approval
MIFEPRISTONE — FDA approval
MIFEPRISTONE
→
May 14, 2021
approval
MIFEPRISTONE — FDA approval
MIFEPRISTONE
→
Jan 3, 2023
approval
MIFEPRISTONE — FDA approval
MIFEPRISTONE
→
Mar 23, 2023
approval
MIFEPRISTONE — FDA approval
MIFEPRISTONE
→
Sep 30, 2025
approval
MIFEPRISTONE — FDA approval
MIFEPRISTONE
→
Sep 30, 2025
approval
MIFEPRISTONE — FDA approval
MIFEPRISTONE
→
Trials studying MIFEPRISTONE
- phase2A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
- —Effectiveness and Safety of Combination Mifepristone/Misoprostol for Medical Abortion
- phase4Study to Determine the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Treatment With Korlym® (Mifepristone) (CATALYST)
- phase2RESET-medication Glucocorticoid Receptor (GR) Blockade As Disease Modifying Treatment for Depression with Childhood Trauma
- phase2REVERSE: Improving Treatment-resistant Post Traumatic Stress Disorder (PTSD) with Glucocorticoid Receptor (GR) Antagonism
- phase2Mifepristone Dynamic Testing for Diagnosis for Central Adrenal Insufficiency
Patent cliff
source: FDA Orange Bookfirst barrier falls
Aug 27, 2028
~1.8 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (18)
- Aug 22, 2038method-of-use (U-1643)US 10231983
- Aug 22, 2038method-of-use (U-1643)US 10314850
- Aug 22, 2038method-of-use (U-1643)US 10780097
- Jun 19, 2037method-of-use (U-1643)US 10195214
- Jun 19, 2037method-of-use (U-1643)US 10842800
- Jun 19, 2037method-of-use (U-1643)US 11969435
- Jun 19, 2037method-of-use (U-1643)US 12097210
- Jan 18, 2037method-of-use (U-1643)US 10151763
- Aug 15, 2036method-of-use (U-1643)US 9829495
- Aug 12, 2036method-of-use (U-1643)US 10006924
- Aug 12, 2036method-of-use (U-1643)US 10495650
- Apr 20, 2036method-of-use (U-1643)US 10166242
- Apr 20, 2036method-of-use (U-1643)US 10166243
- Apr 20, 2036method-of-use (U-1643)US 10660904
- Apr 20, 2036method-of-use (U-1643)US 9943526
- Mar 5, 2033method-of-use (U-1643)US 10500216
- Nov 15, 2032method-of-use (U-1643)US 10842801
- Aug 27, 2028method-of-use (U-1643)US 89213481.8y
News(10)
- White House pulls nomination for FDA nominee OvertonThe sudden end of Heidi Overton’s candidacy likely ensures a Democrat-controlled Congress will choose the FDA’s next leader — but shouldn’t disrupt the agency, analysts say.biopharma_dive · 22h ago
- Heidi Overton’s FDA nomination pulled by White HouseThe White House is pulling Heidi Overton’s nomination to lead the FDA just hours before the Senate was scheduled to vote on her confirmation.fiercebiotech · 1d ago
- FDA finalizes cell and gene therapy potency guidanceIn a final guidance issued on Monday, the US Food and Drug Administration (FDA) laid out its expectations for cell and gene therapy (CGT) sponsors to demonstrate that their products meet potency st…raps · 17d ago
- Mifepristone study highlights need for more transparency, data collection in FDA’s REMS programPatients who reviewed and signed a patient agreement form (PAF) for mifepristone and misoprostol under the US Food and Drug Administration’s (FDA) risk evaluation and mitigation strategy (REMS) pro…raps · 17d ago
- How these census changes could threaten public healthThe Trump administration wants to make three big changes to the U.S. Census, including eliminating questions about race, ethnicity, and sexual orientation and excluding anyone who is not a citizen…stat · 1mo ago
- FDA says its safety review of abortion pill will continue into next yearThe FDA says its ongoing safety review of the nation's main abortion pill will continue into next year, a timeline that was quickly condemned by abortion opponents.stat · 1mo ago
- Trump uses ‘contested’ power to cut more funding to HHSLate Friday night, the Trump administration clawed back nearly $1 billion in spending approved by Congress, targeting several HHS programs focused on immigrants and diversitystat · 1mo ago
- Opinion: FDA commissioner nominee Heidi Overton is ignoring the science on abortion drug“With this latest appointment, mifepristone has a new boss but an old problem,” writes Julie F. Kay, founder and CEO of Reproductive Futures.stat · 1mo ago
- STAT+: Pharmalittle: We’re reading about a reticent FDA commish nominee, a Novo deal, and morePresident Trump’s nominee to lead the FDA was grilled by senators on hot button topics like China, vaccines, and abortion accessstat · 1mo ago
- Federal judge rolls back landmark disability protectionsThe Justice Department said in June that it would no longer enforce laws that prioritized people with disabilities living and receiving services in their communities, rather than in nursing homes…stat · 1mo ago
Data sources
last refreshed 4h ago
Found something off?
comments(0)
5-min edit window · permanent after that